physician prescribing
Recently Published Documents


TOTAL DOCUMENTS

210
(FIVE YEARS 30)

H-INDEX

21
(FIVE YEARS 3)

2021 ◽  
Author(s):  
Michael A. Grasso ◽  
Zachary Kim ◽  
Alexandra Rogalski ◽  
Benjamin Nosrati ◽  
Naveed Farrukh

2021 ◽  
Vol 33 ◽  
pp. S393
Author(s):  
E. Broughton ◽  
M.B. Berry ◽  
R. Montgomery ◽  
A.L. Lambert ◽  
S. Teitsson ◽  
...  

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Melissa L. Rice ◽  
Monica A. Sandoval ◽  
Katherine M. Castleberry ◽  
Terry L. Schwartz

Author(s):  
James Fowler ◽  
Brian W. Rotenberg ◽  
Leigh J. Sowerby

Abstract Background In the specialty of Otolaryngology – Head and Neck Surgery, intranasal corticosteroids are the mainstay treatment for inflammatory processes within the nasal cavity. All too often, physician prescribing patterns are based on previous training, personal experience, and interactions with industry. The purpose of this commentary is to review the nuances of each intranasal corticosteroid. Commentary There are nine intranasal corticosteroids approved for use in Canada. Each are discussed in detail, including their indication, bioavailability, effects on intranasal environment, and factors around patient adherence. Off-label use of budesonide irrigations is also discussed and cost information is presented in reference format for all available intranasal corticosteroids. Conclusion Although the efficacy of each intranasal corticosteroid has been shown to be similar, prescribing should be tailored based on bioavailability, intranasal environment, and factors that impact patient adherence such as dosing, cost and tolerability. Graphical abstract


Author(s):  
Aaron P. Mitchell ◽  
Niti U. Trivedi ◽  
Renee L. Gennarelli ◽  
Susan Chimonas ◽  
Sara M. Tabatabai ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document